This study aims to evaluate the food-effect of tegoprazan 50mg on the pharmacokinetics and pharmacodynamics in healthy H. pylori negative male volunteers
Primary Outcome Measure: 1. AUClast and Cmax of tegaprazan 2. Gastric pH
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
12
K-CAB
Seoul National University Hospital, Clinical Trial Center
Seoul, South Korea
AUClast of tegaprazan
Area under the plasma concentration versus time curve of tegoprazan
Time frame: Pre-dose(0 hour) and up to 48 hours in each period
Cmax of tegaprazan
Peak Plasma Concentration of tegoprazan
Time frame: Pre-dose(0 hour) and up to 48 hours in each period
Gastric pH
Gastric pH
Time frame: Pre-dose(0 hour) up to 24 hours after Investigational product administration in each period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.